Alexander Idu Entonu

Alexander Idu Entonu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GAGambo Sidi Ali
Gambo Sidi Ali
AOAbraham Oloture Ogwuche
Abraham Oloture Ogwuche
AEAlexander Idu Entonu
Alexander Idu Entonu
KDKabir Adekunle Durowade
Kabir Adekunle Durowade
Stigmatization and discrimination toward people living with HIV/AIDS (PLWHA) continue to be significant hurdles to successful treatment and social integration, especially in Nigeria. These barriers have a negative impact on mental health, deter disclosure, and reduce access to healthcare. The purpose of this study was to determine the prevalence, types, and causes of stigma and discrimination among PLWHA receiving antiretroviral therapy (ART) in Ikeja, Lagos State, Nigeria. A cross-sectional study of 400 PLWHA on ART was done at three randomly chosen treatment centers. Structured questionnaires and the Berger HIV Stigma Scale were used to collect information about individualized stigma, disclosure concerns, negative self-image, and public attitudes. The statistical study used descriptive statistics, chi-square tests, and logistic regression, with a significance level of p < 0.05. Overall, 37.7% of individuals reported stigma in hospital settings, 41.5% received negative attitudes from family or friends, and 48.7% felt ashamed or condemned because of their situation. Fear of revelation was widespread, with 65% refusing to declare their status. Stigma had a major impact on mental health (64.3%) and reduced ART access for 39.7% of responders. Younger age (20–39 years), poor income, HIV-positive partners, and disclosure of status were all significant predictors of stigmatization. Discrimination was highly related to occupation, gender, and socioeconomic status. Stigma and discrimination continue to be pervasive in Ikeja, limiting PLWHA access to healthcare and negatively impacting their psychological well-being. To establish a more inclusive and supportive environment, it is necessary to enhance anti-discrimination regulations, train healthcare providers, educate the public, and implement socioeconomic empowerment activities.

26 May 2025 in Discover Public Health
Verified
Journal Article
Open access
PDF file
BABabatunde Enoch Adewumi
Babatunde Enoch Adewumi
JDJulius Kolajo Dare
Julius Kolajo Dare
RARita Omobosola Alabi
Rita Omobosola Alabi
RKRosemary Oluwatosin Komolafe
Rosemary Oluwatosin Komolafe
SASonnen Atinge
Sonnen Atinge
AEAlexander Idu Entonu
Alexander Idu Entonu
Cervical dysplasia is a precancerous condition characterized by abnormal cell growth in the cervix. It is a global health concern, particularly in low-reso

19 February 2026 in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Verified
Journal Article
Open access
PDF file
NANicholas Aderinto
Nicholas Aderinto
EBEmmanuel Adeoba Babawale
Emmanuel Adeoba Babawale
GOGbolahan Olatunji
Gbolahan Olatunji
EKEmmanuel Kokori
Emmanuel Kokori
FBFestus Oluseye Babarinde
Festus Oluseye Babarinde
CUChidinma Udojike
Chidinma Udojike
Ischemic stroke remains a leading cause of mortality and long-term disability worldwide, necessitating innovative therapeutic approaches beyond conventional treatments. RNA-based therapeutics have emerged as a promising strategy to modulate key pathological processes involved in stroke, including neuroinflammation, apoptosis, oxidative stress, and neurovascular dysfunction. Small interfering RNA (siRNA) and microRNA (miRNA)-based therapies enable post-transcriptional gene silencing to downregulate deleterious pathways, while messenger RNA (mRNA) and long non-coding RNA (lncRNA)-based strategies promote neuroprotection and neuronal recovery. Despite significant preclinical advancements, several challenges hinder clinical translation, including blood-brain barrier (BBB) permeability, RNA stability, immune responses, off-target effects, and efficient intracellular delivery. Recent breakthroughs in nanoparticle-based delivery systems, exosome-mediated transport, and CRISPR-based RNA editing offer novel solutions to these limitations, paving the way for precision medicine approaches in stroke treatment. Future research must focus on optimizing RNA formulations, refining delivery mechanisms, and conducting rigorous clinical trials to establish their safety and efficacy in stroke patients. If successfully translated into clinical practice, RNA-based therapeutics have the potential to revolutionize stroke management by providing targeted, disease-modifying interventions that enhance functional recovery and reduce long-term neurological deficits.

22 January 2026 in Egyptian Pediatric Association Gazette
Verified
Journal Article
Open access
PDF file
Chidera Stanley AnthonyChidera Stanley Anthony
Chidera Stanley Anthony
IOIKPONMWOSA JUDE OGIEUHI
IKPONMWOSA JUDE OGIEUHI
AEAlexander Idu Entonu
Alexander Idu Entonu
NBNwamaka Chidera Bob-Ume
Nwamaka Chidera Bob-Ume
OAOlufemi Akinmeji
Olufemi Akinmeji
CAChinonyelum Emmanuel Agbo
Chinonyelum Emmanuel Agbo
Background: Congenital heart disease (CHD) is a major cause of child morbidity and mortality across Africa. Despite increased recognition of CHD as a significant public health challenge, surgical services remain geographically and institutionally limited. Individual reports and studies have shown widely varied surgical outcomes for pediatrics in Africa. Hence, there is a need to obtain consolidated evidence on these outcomes to guide policies. This study systematically analyzes the surgical outcomes of CHD among African pediatric populations. Method: Using the PRISMA guidelines, we searched databases including PubMed, Google Scholar, Scopus, Web of Science, and AJOL. Boolean operators (AND, OR) were used appropriately to combine the keywords. We then screened articles for eligibility, ensuring that only studies with surgical interventions comprising the pediatric African population were selected. Results: A total of 2,843 records were screened, of which 18 eligible studies were included. The median age of the included population ranged from about 2 years to 15 years. The postoperative mortality ranged from approximately 0% to 13%. In many cases, patients presented late, often with advanced disease and comorbidities. The median hospital stay ranged from 7 to 19 days. Centers with locally trained cardiac surgeons had better survival rates than those reliant solely on visiting international missions. Conclusion: There are wide systemic inequities in terms of the availability of surgical services and outcome measures such as mortality and complications. There is a need to invest adequately in pediatric cardiac programs to ensure the availability of highly-skilled local cardiologists and adequate infrastructure.

6 July 2026 in Egyptian Pediatric Association Gazette
Verified
Journal Article
Open access
PDF file
NBNwamaka Chidera Bob-Ume
Nwamaka Chidera Bob-Ume
KUKingsley Ayi Ukpanyang
Kingsley Ayi Ukpanyang
Chidera Stanley AnthonyChidera Stanley Anthony
Chidera Stanley Anthony
AEAlexander Idu Entonu
Alexander Idu Entonu
IOIbukun Oyebimpe Oyeleke
Ibukun Oyebimpe Oyeleke
IOIKPONMWOSA JUDE OGIEUHI
IKPONMWOSA JUDE OGIEUHI
Background: Primary congenital glaucoma (PCG) is an uncommon but serious cause of childhood visual loss. In African settings, children often present late, with advanced disease. However, the evidence on treatment outcomes and barriers to care has not yet been comprehensively mapped. Methods: We searched PubMed, Scopus, Google Scholar, EMBASE, Web of Science, African Journals Online, and African Index Medicus for English-language studies published between January 2011 and January 2026. Eligible studies reported treatment approaches, outcomes, complications, or barriers to care for children with PCG in Africa. Findings were synthesized narratively. Results: Ten studies involving 746 eyes from Tanzania, Ghana, Nigeria, Senegal, Ethiopia, Egypt, and Tunisia were included. Most were retrospective single-center studies. Mean age at presentation, where reported, ranged from 4.8 ± 3.6 months in Nigeria to 2.7 years in Ethiopia, while mean age at diagnosis was reported as 4.4 months in Ghana and 19 months in Tanzania. Mean age at surgery was reported as 5.2 ± 2.9 months in the Nile Delta cohort in Egypt, 5.9 months in Tunisia, and 8.1 ± 5.9 months in Nigeria. Bilateral disease, corneal edema, enlarged corneal diameters, and raised intraocular pressure were commonly reported. Surgery was the main reported treatment approach. Combined trabeculotomy-trabeculectomy was commonly used in more advanced cases, while angle procedures were used when corneal clarity allowed. Postoperative intraocular pressure reduction was reported, and short- to medium-term surgical success ranged from 72.7% to 91.6%. Longer follow-up showed a decline from 91.6% at 1 year to 54.3% at 10 years in Tunisia. Visual outcomes were less consistent, and poor follow-up, delayed referral, limited surgical infrastructure, and cost were frequently reported barriers. Conclusion: PCG in African children remains marked by delayed diagnosis, advanced disease at presentation, and barriers to care. Improving outcomes will likely require earlier recognition, stronger referral and follow-up systems, wider access to pediatric glaucoma expertise, and more robust multicenter prospective research.